News

This patent, along with related patents issued in June 2013 (US Patent no. 8,461,157) and February 2013 (US Patent No. 8,367,663), covers a broad range of proprietary chemical

Financial terms of the agreement were not disclosed by the two companies. Pursuant to the terms of the agreement, Sofgen Pharmaceuticals will be responsible for development, manufacturing and

Alcobra president and CEO Dr Yaron Daniely noted that the company is pleased that the USPTO granted us this second important patent. "As we expand clinical trials and

The NAPOLI-1 Phase III study was conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. The primary log-rank analysis of overall survival was statistically significant

Preclinical data that supported this approval will be presented in a poster session at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) on 6 May

The option grants the potential commercial partner an exclusive, time-limited right to negotiate, in good faith, the terms of a definitive license agreement with respect to development, distribution

TRV130 is a small molecule G protein biased ligand at the mu opioid receptor. Phase IIa/b study is a multicenter, randomized trial designed to assess the effects of

The Phase I study is Complexa’s first human clinical trial designed to assess the safety and pharmacokinetics of its CXA-10. With the use of various biomarkers, this study

Purixan is a 20mg/ml oral suspension of existing ALL treatment mercaptopurine. Prior to Xaluprine and Purixan, mercaptopurine has only been available as a 50mg tablet for many years.